


# INTELLOTRACKER

## PHARMACOGENOMICS & PRECISION MEDICINE

JUNE 2023



### ARANCA'S QUARTERLY SECTORIAL UPDATE ACROSS FOUR DIMENSIONS....





## DEVELOPMENTS

Under-research technologies		Groundbreaking research demonstrates the power of using personalized approaches to select and correctly apply pharmaceuticals to patients. Source: <a href="#">European Commission</a>
Under-research technologies		The British Pharmacological Society called for pharmacogenomic testing to be embedded into NHS practice, citing a new study that shows implementation could reduce adverse drug reactions by 30%. Source: <a href="#">British Pharmacological Society</a>
Under-research technologies		A new prediction tool uses artificial intelligence and genetics to predict the risk for complications from chemotherapy drug toxicity in patients with acute lymphoblastic leukemia (ALL) at the University of Florida. Source: <a href="#">Tech Target Blog</a>
Under-research technologies		A study by researchers at the UMich College of Pharmacy explores prevalence of Drug-Gene Interactions, offers recommendations for implementing pharmacogenetics services. Source: <a href="#">University of Michigan Blog</a>
New product launches		University of California, San Francisco Health will launch a clinical pharmacogenetics program which is supported by two automated clinical decision-support (CDS) systems embedded in UCSF Health's Epic Systems electronic health records. Source: <a href="#">Precision Medicine Online</a>
Technology updates		Scientists at St. Jude Children's Research Hospital have conducted a groundbreaking study on drug response variations in genetic subtypes of acute lymphoblastic leukemia, offering a blueprint for personalized precision medicine. Source: <a href="#">Science Daily Blog</a>
Technology updates		The FDA established precisionFDA, a cloud-based portal, to foster global collaboration and research in personalized medicine, facilitating the testing, validation, and development of innovative technology and bioinformatics methods for NGS processing. Source: <a href="#">US Pharmacist Blog</a>



## DYNAMICS

Other initiatives		Ochsner Health becomes a national leader in precision medicine by implementing universal genomic testing for chemotherapy, specifically for cancer patients receiving 5-fluorouracil and capecitabine. Source: <a href="#">Ochsner Health News</a>
Other initiatives		A consortium led by the University of Tartu and Tartu University Hospital in Estonia has been awarded €30 million (\$33 million) to create a personalized medicine research and development center of excellence. Source: <a href="#">Genome Web Blog</a>



## DIVERSIFICATION

Company collaboration		Genomic Medicine Sweden launches collaboration with Microsoft in cloud computing, AI and visualization. The collaboration will enable the vast amount of data generated in precision medicine to be put to the best possible use for patients and research. Source: <a href="#">Genomic Medicine Sweden Blog</a>
Company collaboration		ACEGID and Illumina establish a joint training academy to boost Africa's genomics capacity and enhance technical expertise in next-generation sequencing, wet lab management, bioinformatics, big data analytics, and AI/ML applications. Source: <a href="#">African Centre of Excellence for Genomics of Infectious Diseases</a>
Mergers & acquisitions		Apollomics completed its merger with special purpose acquisition company Maxpro Capital Acquisition. Apollomics has several targeted therapies in clinical development to help advance development of its oncology pipeline. Source: <a href="#">Precision Medicine Online</a>
Mergers & acquisitions		Jounce Therapeutics announced it will be acquired by Concentra Biosciences for \$1.85 in cash per share plus a non-tradeable contingent value right (CVR). Source: <a href="#">Precision Medicine Online</a>



## DRIVERS

Government regulations		EMA's Regulatory Science Strategy for 2025 aims to create a Methodologies Working Party covering various areas like biostatistics, modeling, pharmacokinetics, and establish an Omics Working Party to strengthen the existing pharmacogenomics group. Source: <a href="#">EMA Europa Document</a>
Others		Genomadix received FDA clearance for its "Genomadix Cube™ CYP2C19 System," assisting clinicians in drug therapy decisions for a number of precision medicine indications, involving the CYP450 2C19 genetic pathway. Source: <a href="#">NewsWire CA</a>

Others



The Scottish Government in collaboration with NHS Scotland aims to motivate & accelerate Scotland's thriving Life Sciences and Precision Medicine Sector & stimulate economic growth through the development & application of genomic technologies.  
 Source: [Scotland Government Document](#)

## SOLUTION PORTFOLIO – TECHNOLOGY RESEARCH & ADVISORY

IP STRATEGY	TECHNOLOGY INTELLIGENCE	GROWTH & STRATEGY
<p>How best can we proactively manage and monetise our technical knowhow / intellectual property?</p>	<p>How best can we keep abreast of technology trends, competitor activity and headwinds / tailwinds in our domain?</p>	<p>Which technologies do we invest in?                      How do we ensure quick wins?                      Speed to market?</p>
<ul style="list-style-type: none"> <li>IP Portfolio Analysis</li> </ul>	<ul style="list-style-type: none"> <li>Competitor Benchmarking</li> </ul>	<ul style="list-style-type: none"> <li>R&amp;D Strategy Roadmaps</li> </ul>
<ul style="list-style-type: none"> <li>IP Monetisation</li> </ul>	<ul style="list-style-type: none"> <li>Tech / IP Landscapes</li> </ul>	<ul style="list-style-type: none"> <li>Technology Scouting</li> </ul>
<ul style="list-style-type: none"> <li>IP Valuation</li> </ul>	<ul style="list-style-type: none"> <li>Technology Watch</li> </ul>	<ul style="list-style-type: none"> <li>Open Innovation</li> </ul>
<ul style="list-style-type: none"> <li>Prior Art Searches</li> </ul>	<ul style="list-style-type: none"> <li>Market Analysis / Trends</li> </ul>	<ul style="list-style-type: none"> <li>Product Development</li> </ul>



GROWTH ADVISORY



INVESTMENT RESEARCH & ANALYTICS



VALUATION & FINANCIAL ADVISORY



TECHNOLOGY RESEARCH & ADVISORY



PROCUREMENT & SUPPLY CHAIN INTELLIGENCE

This material is exclusive property of Aranca. No part of this presentation may be used, shared, modified and/or disseminated without permission. All rights reserved.